Headquartered in Lexington, MA Fiscal year ends December NASDAQ: VYGR voyagertherapeutics.com
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company focused on leveraging human genetics to modify the course of and treat neurological diseases. The company's pipeline includes programs targeting Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other central nervous system disorders. Voyager's proprietary TRACER AAV capsid discovery platform generates novel capsids and identifies associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. The company's key wholly-owned clinical-stage programs include VY7523, an anti-tau antibody, and VY1706, a tau-silencing gene therapy, both targeting Alzheimer's disease. Voyager also has collaboration partnerships with Alexion (AstraZeneca Rare Disease), Novartis Pharma AG, and Neurocrine Biosciences, with the Neurocrine partnership advancing NBIB-'223 for Friedreich's ataxia. Revenue is currently derived from collaboration agreements rather than product sales. Updated
On the June 30 episode of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer about Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company he wanted to hold for…
Omor Ibne Ehsan Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company focused on leveraging human genetics to modify the course of and treat neurological diseases.
The Wall Street consensus 12-month price target for VYGR is $14.89.